{"id":"cefuroxime-750mg-i-v","safety":{"commonSideEffects":[{"rate":"2-3%","effect":"Diarrhea"},{"rate":"1-2%","effect":"Nausea"},{"rate":"1%","effect":"Vomiting"},{"rate":"1-2%","effect":"Phlebitis at injection site"},{"rate":"1-3%","effect":"Hypersensitivity reactions"},{"rate":"1%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2146124","moleculeType":"Small molecule","molecularWeight":"446.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cefuroxime works by disrupting the cross-linking of peptidoglycan in bacterial cell walls, leading to cell wall instability and bacterial death. It has broad-spectrum activity against both gram-positive and gram-negative bacteria, making it effective against a wide range of infections. The 750mg I.V. formulation provides rapid systemic delivery for serious infections requiring parenteral administration.","oneSentence":"Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:51.302Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections including lower respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, and meningitis"},{"name":"Perioperative prophylaxis in surgical procedures"}]},"trialDetails":[{"nctId":"NCT04161599","phase":"PHASE4","title":"Preoperative Oral Antibiotics With vs Without Mechanical Bowel Preparation to Reduce Surgical Site Infections Following Colonic Resection: an International Randomized Controlled Trial.","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2022-03-01","conditions":"Wounds and Injuries, Surgery--Complications","enrollment":968},{"nctId":"NCT02505581","phase":"PHASE4","title":"Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-05","conditions":"Surgical Wound Infection","enrollment":536}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cefuroxime (750mg) I.V","genericName":"Cefuroxime (750mg) I.V","companyName":"Hospital Universitari Vall d'Hebron Research Institute","companyId":"hospital-universitari-vall-d-hebron-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections including lower respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, and meningitis, Perioperative prophylaxis in surgical procedures.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}